Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Charles L. Raison, Andrey S. Borisov, Sherry D. Broadwell, Lucile Capuron, Bobbi J. Woolwine, Ira M. Jacobson, Charles Nemeroff, Andrew H. Miller

Research output: Contribution to journalArticle

256 Citations (Scopus)

Abstract

BACKGROUND: Interferon-alpha (IFN-alpha) plus ribavirin is used to treat hepatitis C virus (HCV) infection and is associated with a high rate of depression. Newer, pegylated preparations of IFN-alpha have a longer half-life, require once-per-week dosing, and may be associated with reduced neuropsychiatric burden. Limited data exist on depression during pegylated IFN-alpha therapy. METHOD: Depressive symptoms were assessed using the Zung Self-Rating Depression Scale (SDS) in 162 HCV-infected patients at baseline and after 4, 8, 12, and 24 weeks of treatment with pegylated IFN alpha-2b (PEG IFN) plus weight-based (N = 86) versus standard dose (N = 76) ribavirin. Data were collected from March 2001 to April 2003. RESULTS: Compared with baseline, mean SDS index scores were significantly increased by week 4 and remained elevated throughout the study. Thirty-nine percent of the sample experienced moderate to severe depressive symptoms (SDS index score > or = 60) at some point during PEG IFN/ribavirin therapy. Baseline depression scores significantly predicted severity of depressive symptoms during PEG IFN/ribavirin treatment (simple regression analysis: Y = 0.55X + 32.7, p < .0001). In addition, assignment to weight-based ribavirin treatment and history of depression were associated with increased likelihood of developing moderate to severe depressive symptoms (odds ratio [OR] = 2.7, 95% CI = 1.3 to 5.6, p < .01, and OR = 3.3, 95% CI = 1.3 to 8.1, p < .01, respectively). CONCLUSIONS: Development of moderate to severe depressive symptoms occurred frequently during PEG IFN/ribavirin treatment and was predicted by baseline depression scores and higher doses of ribavirin. History of major depressive disorder was also a significant predictive factor, but only through association with elevated baseline depression status. All of these factors can be evaluated and addressed to limit neuropsychiatric morbidity during HCV treatment.

Original languageEnglish
Pages (from-to)41-48
Number of pages8
JournalThe Journal of clinical psychiatry
Volume66
Issue number1
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Ribavirin
Interferon-alpha
Depression
Therapeutics
Hepacivirus
Odds Ratio
Weights and Measures
Major Depressive Disorder
Virus Diseases
Half-Life

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., ... Miller, A. H. (2005). Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. The Journal of clinical psychiatry, 66(1), 41-48.

Depression during pegylated interferon-alpha plus ribavirin therapy : prevalence and prediction. / Raison, Charles L.; Borisov, Andrey S.; Broadwell, Sherry D.; Capuron, Lucile; Woolwine, Bobbi J.; Jacobson, Ira M.; Nemeroff, Charles; Miller, Andrew H.

In: The Journal of clinical psychiatry, Vol. 66, No. 1, 01.01.2005, p. 41-48.

Research output: Contribution to journalArticle

Raison, CL, Borisov, AS, Broadwell, SD, Capuron, L, Woolwine, BJ, Jacobson, IM, Nemeroff, C & Miller, AH 2005, 'Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.', The Journal of clinical psychiatry, vol. 66, no. 1, pp. 41-48.
Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. The Journal of clinical psychiatry. 2005 Jan 1;66(1):41-48.
Raison, Charles L. ; Borisov, Andrey S. ; Broadwell, Sherry D. ; Capuron, Lucile ; Woolwine, Bobbi J. ; Jacobson, Ira M. ; Nemeroff, Charles ; Miller, Andrew H. / Depression during pegylated interferon-alpha plus ribavirin therapy : prevalence and prediction. In: The Journal of clinical psychiatry. 2005 ; Vol. 66, No. 1. pp. 41-48.
@article{b9e4a96866e74eb8a7c179e90f927e21,
title = "Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.",
abstract = "BACKGROUND: Interferon-alpha (IFN-alpha) plus ribavirin is used to treat hepatitis C virus (HCV) infection and is associated with a high rate of depression. Newer, pegylated preparations of IFN-alpha have a longer half-life, require once-per-week dosing, and may be associated with reduced neuropsychiatric burden. Limited data exist on depression during pegylated IFN-alpha therapy. METHOD: Depressive symptoms were assessed using the Zung Self-Rating Depression Scale (SDS) in 162 HCV-infected patients at baseline and after 4, 8, 12, and 24 weeks of treatment with pegylated IFN alpha-2b (PEG IFN) plus weight-based (N = 86) versus standard dose (N = 76) ribavirin. Data were collected from March 2001 to April 2003. RESULTS: Compared with baseline, mean SDS index scores were significantly increased by week 4 and remained elevated throughout the study. Thirty-nine percent of the sample experienced moderate to severe depressive symptoms (SDS index score > or = 60) at some point during PEG IFN/ribavirin therapy. Baseline depression scores significantly predicted severity of depressive symptoms during PEG IFN/ribavirin treatment (simple regression analysis: Y = 0.55X + 32.7, p < .0001). In addition, assignment to weight-based ribavirin treatment and history of depression were associated with increased likelihood of developing moderate to severe depressive symptoms (odds ratio [OR] = 2.7, 95{\%} CI = 1.3 to 5.6, p < .01, and OR = 3.3, 95{\%} CI = 1.3 to 8.1, p < .01, respectively). CONCLUSIONS: Development of moderate to severe depressive symptoms occurred frequently during PEG IFN/ribavirin treatment and was predicted by baseline depression scores and higher doses of ribavirin. History of major depressive disorder was also a significant predictive factor, but only through association with elevated baseline depression status. All of these factors can be evaluated and addressed to limit neuropsychiatric morbidity during HCV treatment.",
author = "Raison, {Charles L.} and Borisov, {Andrey S.} and Broadwell, {Sherry D.} and Lucile Capuron and Woolwine, {Bobbi J.} and Jacobson, {Ira M.} and Charles Nemeroff and Miller, {Andrew H.}",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "66",
pages = "41--48",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "1",

}

TY - JOUR

T1 - Depression during pegylated interferon-alpha plus ribavirin therapy

T2 - prevalence and prediction.

AU - Raison, Charles L.

AU - Borisov, Andrey S.

AU - Broadwell, Sherry D.

AU - Capuron, Lucile

AU - Woolwine, Bobbi J.

AU - Jacobson, Ira M.

AU - Nemeroff, Charles

AU - Miller, Andrew H.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - BACKGROUND: Interferon-alpha (IFN-alpha) plus ribavirin is used to treat hepatitis C virus (HCV) infection and is associated with a high rate of depression. Newer, pegylated preparations of IFN-alpha have a longer half-life, require once-per-week dosing, and may be associated with reduced neuropsychiatric burden. Limited data exist on depression during pegylated IFN-alpha therapy. METHOD: Depressive symptoms were assessed using the Zung Self-Rating Depression Scale (SDS) in 162 HCV-infected patients at baseline and after 4, 8, 12, and 24 weeks of treatment with pegylated IFN alpha-2b (PEG IFN) plus weight-based (N = 86) versus standard dose (N = 76) ribavirin. Data were collected from March 2001 to April 2003. RESULTS: Compared with baseline, mean SDS index scores were significantly increased by week 4 and remained elevated throughout the study. Thirty-nine percent of the sample experienced moderate to severe depressive symptoms (SDS index score > or = 60) at some point during PEG IFN/ribavirin therapy. Baseline depression scores significantly predicted severity of depressive symptoms during PEG IFN/ribavirin treatment (simple regression analysis: Y = 0.55X + 32.7, p < .0001). In addition, assignment to weight-based ribavirin treatment and history of depression were associated with increased likelihood of developing moderate to severe depressive symptoms (odds ratio [OR] = 2.7, 95% CI = 1.3 to 5.6, p < .01, and OR = 3.3, 95% CI = 1.3 to 8.1, p < .01, respectively). CONCLUSIONS: Development of moderate to severe depressive symptoms occurred frequently during PEG IFN/ribavirin treatment and was predicted by baseline depression scores and higher doses of ribavirin. History of major depressive disorder was also a significant predictive factor, but only through association with elevated baseline depression status. All of these factors can be evaluated and addressed to limit neuropsychiatric morbidity during HCV treatment.

AB - BACKGROUND: Interferon-alpha (IFN-alpha) plus ribavirin is used to treat hepatitis C virus (HCV) infection and is associated with a high rate of depression. Newer, pegylated preparations of IFN-alpha have a longer half-life, require once-per-week dosing, and may be associated with reduced neuropsychiatric burden. Limited data exist on depression during pegylated IFN-alpha therapy. METHOD: Depressive symptoms were assessed using the Zung Self-Rating Depression Scale (SDS) in 162 HCV-infected patients at baseline and after 4, 8, 12, and 24 weeks of treatment with pegylated IFN alpha-2b (PEG IFN) plus weight-based (N = 86) versus standard dose (N = 76) ribavirin. Data were collected from March 2001 to April 2003. RESULTS: Compared with baseline, mean SDS index scores were significantly increased by week 4 and remained elevated throughout the study. Thirty-nine percent of the sample experienced moderate to severe depressive symptoms (SDS index score > or = 60) at some point during PEG IFN/ribavirin therapy. Baseline depression scores significantly predicted severity of depressive symptoms during PEG IFN/ribavirin treatment (simple regression analysis: Y = 0.55X + 32.7, p < .0001). In addition, assignment to weight-based ribavirin treatment and history of depression were associated with increased likelihood of developing moderate to severe depressive symptoms (odds ratio [OR] = 2.7, 95% CI = 1.3 to 5.6, p < .01, and OR = 3.3, 95% CI = 1.3 to 8.1, p < .01, respectively). CONCLUSIONS: Development of moderate to severe depressive symptoms occurred frequently during PEG IFN/ribavirin treatment and was predicted by baseline depression scores and higher doses of ribavirin. History of major depressive disorder was also a significant predictive factor, but only through association with elevated baseline depression status. All of these factors can be evaluated and addressed to limit neuropsychiatric morbidity during HCV treatment.

UR - http://www.scopus.com/inward/record.url?scp=13844306621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844306621&partnerID=8YFLogxK

M3 - Article

C2 - 15669887

AN - SCOPUS:13844306621

VL - 66

SP - 41

EP - 48

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 1

ER -